Why Is Molecular Cancer Profiling Accelerating Growth in the Clinical Oncology Next Generation Seque
Author : DheerajV Patil | Published On : 01 Oct 2026
The global clinical oncology next generation sequencing market is experiencing strong growth due to increasing demand for precision oncology, rising adoption of genomic testing in cancer diagnosis, growing use of molecular profiling for treatment selection, and continuous advancements in sequencing technologies. The global clinical oncology next generation sequencing market size was valued at USD 628.45 million in 2025 and is projected to grow from USD 695.95 million in 2026 to USD 1574.02 million by 2034, registering a CAGR of 10.74% during the forecast period from 2026 to 2034.
Next-generation sequencing enables comprehensive analysis of genetic alterations associated with cancer, supporting the identification of mutations, biomarkers, and other genomic characteristics. Increasing integration of genomic information into clinical decision-making is encouraging hospitals, diagnostic laboratories, pharmaceutical companies, and research institutions to adopt sequencing-based oncology testing.
Market Drivers
Growing Adoption of Precision Oncology
The increasing focus on personalized cancer treatment is driving demand for genomic testing. Next-generation sequencing can identify multiple genetic alterations from a single sample, helping clinicians understand tumor characteristics and select targeted treatment strategies based on individual molecular profiles.
Rising Demand for Molecular Cancer Profiling
Cancer treatment increasingly relies on identifying specific genomic biomarkers that can influence therapeutic decisions. NGS-based molecular profiling enables simultaneous analysis of multiple genes and mutations, supporting more comprehensive characterization of tumors across different cancer types.
Increasing Availability of Targeted Therapies
The development of targeted cancer therapies is increasing the importance of companion diagnostics and genomic testing. Pharmaceutical companies and healthcare providers are using molecular information to identify patients who may benefit from specific therapies, supporting demand for clinical oncology sequencing.
Advancements in Sequencing Technologies
Continuous improvements in sequencing platforms, bioinformatics, sample preparation, and data analysis are improving the efficiency and capabilities of NGS testing. Faster workflows, broader gene panels, and improved analytical accuracy are supporting wider clinical adoption.
Market Challenges
High Cost of NGS Testing
NGS-based oncology testing requires specialized sequencing instruments, reagents, bioinformatics infrastructure, and trained professionals. The overall cost of testing can remain high, particularly for smaller healthcare facilities and laboratories with limited resources.
Complex Data Interpretation
Clinical NGS generates large volumes of genomic data that require sophisticated bioinformatics tools and specialized expertise for interpretation. Identifying clinically relevant mutations and distinguishing actionable variants from uncertain findings can create challenges for healthcare providers.
Regulatory and Reimbursement Challenges
Differences in regulatory requirements, testing standards, and reimbursement policies can affect the adoption of clinical NGS. Limited reimbursement coverage for certain genomic tests may also restrict access in some healthcare systems.
Market Segmentation
By Technology:
- Sequencing by Synthesis
- Ion Semiconductor Sequencing
- Single-Molecule Real-Time Sequencing
- Nanopore Sequencing
- Others
Sequencing by synthesis represents an important technology category due to its broad application in clinical genomic testing and established sequencing capabilities. Emerging sequencing technologies are also gaining attention because of their potential to improve speed, flexibility, and testing efficiency.
By Product and Service:
- Consumables
- Instruments
- Services
Consumables represent a significant product category because sequencing workflows require recurring use of reagents, kits, and other laboratory materials. Sequencing services are also increasingly used by healthcare organizations that prefer to outsource specialized genomic testing.
By Application:
- Biomarker Screening
- Companion Diagnostics
- Precision Medicine
- Clinical Research
- Others
Precision medicine represents a significant application area as healthcare providers increasingly use genomic information to support individualized cancer treatment. Companion diagnostics and biomarker screening are also expanding alongside the development of targeted therapies.
By End User:
- Hospitals and Clinics
- Diagnostic Laboratories
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Others
Hospitals and clinics represent important end users as genomic testing becomes increasingly integrated into oncology diagnosis and treatment planning. Pharmaceutical and biotechnology companies also use NGS extensively in drug development and biomarker research.
Regional Insights
North America
North America represents a significant market due to advanced healthcare infrastructure, strong adoption of precision medicine, extensive cancer research activities, and the presence of major sequencing technology providers. The United States remains a major contributor to regional growth.
Europe
Europe represents an important market supported by expanding genomic medicine programs, cancer research initiatives, advanced diagnostic infrastructure, and increasing integration of molecular testing into clinical oncology. Growing healthcare investments are supporting adoption across major European countries.
Asia-Pacific
Asia-Pacific is expected to witness strong growth during the forecast period owing to increasing cancer incidence, expanding healthcare infrastructure, rising genomic research activities, and growing adoption of precision medicine. China, Japan, South Korea, India, and Australia are creating significant opportunities for clinical NGS providers.
Latin America, Middle East, and Africa
These regions represent emerging markets as healthcare systems expand access to advanced diagnostics and genomic technologies. Increasing cancer research, investments in laboratory infrastructure, and growing awareness of precision oncology are supporting market opportunities.
Key Players Analysis
The clinical oncology next generation sequencing market is competitive, with companies focusing on sequencing technology innovation, oncology-focused testing solutions, bioinformatics, diagnostic partnerships, and clinical applications. Key players include:
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- Agilent Technologies, Inc.
- BGI Genomics Co., Ltd.
- Foundation Medicine, Inc.
- Guardant Health, Inc.
- NeoGenomics Laboratories, Inc.
- Laboratory Corporation of America Holdings
These companies are investing in advanced sequencing platforms, oncology gene panels, companion diagnostic solutions, liquid biopsy technologies, and bioinformatics capabilities to support the growing use of genomic testing in cancer care.
For Detailed Insights, Visit:
https://straitsresearch.com/report/clinical-oncology-next-generation-sequencing-market
About Us
Straits Research is a leading market research and consulting organization providing industry reports, business intelligence, and strategic insights across a wide range of industries. Its research helps businesses understand market dynamics, emerging opportunities, competitive landscapes, and industry trends to support informed business decisions.
Contact Us
Email: [email protected]
Tel: +1 646 905 0080 (U.S.)
Tel: +44 203 695 0070 (U.K.)
